The cost-effectiveness of paliperidone extended release in Spain

References

• Eusko Jaurlaritza Gobierno Vasco. Informe análisis de impacto presupuestario Paliperidona. Departamento de Sanidad GV 2009.
   Google Scholar
• Oliva-Moreno J, Lopez-Bastida J, Osuna-Guerrero R, et al. The costs of schizophrenia in Spain. Eur J Health Econ 2006;7:182-8
   PubMedGoogle Scholar
• Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16:31-43
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
   PubMed Web of Science ®Google Scholar
• Canuso CM, Youssef EA, Bossie CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-15
   PubMed Web of Science ®Google Scholar
• Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166:691-701
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (Update), Chapter 7.2. 2009 http://www.ncbi.nlm.nih.gov/books/NBK11681/pdf/TOC.pdf. Accessed October 16, 2012
   Google Scholar
• Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23:17-33
   PubMed Web of Science ®Google Scholar
• Laux G, Heeg BMS, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:49-61
   PubMed Web of Science ®Google Scholar
• Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23:62-74
   PubMed Web of Science ®Google Scholar
• Hensen M, Heeg B, Lothgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy 2010;8:327-41
   PubMedGoogle Scholar
• Larsen TK, Moe LC, Vibe-Hansen L, et al. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000;29:1-9
   Google Scholar
• Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004;65:551-6
   PubMed Web of Science ®Google Scholar
• Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51:531-9
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Engelhart L, Janagap C, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275-86
   PubMed Web of Science ®Google Scholar
• Lenert L, Sturley A, Rapaport M, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
   PubMed Web of Science ®Google Scholar
• Zhou H, Isaman DJM, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:2856-63
   PubMed Web of Science ®Google Scholar
• Landy J, Stein J, Brown MM, et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002;8:CR543-8
   PubMedGoogle Scholar
• Siddique R, Markowitz J, Engelhart L. Impact of atypical antipsychotic drug sedation on quality of life. Atlanta, Georgia: American Psychiatric Assocociation, 2005.
   Google Scholar
• Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperisone on risk of diabetes among patients with schizophreia: population based nested case-control study. BMJ 2002;325:243
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson Pharmaceutical Research. Extended Release OROS Paliperidone in the Treatment of Schizophrenia. Module 2.5 - Clinical Overview. R076477. New Brunswick, New Jersey, USA: Johnson & Johnson Pharmaceutical Research, 2006.
   Google Scholar
• Johnson & Johnson Pharmaceutical Research. Extended Release OROS Paliperidone in the Treatment of Schizophrenia. Module 2.7.3 - Summary of Clinical Evidence. New Brunswick, New Jersey, USA: Johnson & Johnson Pharmaceutical Research, 2005.
   Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
   PubMed Web of Science ®Google Scholar
• Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD005237
   Google Scholar
• Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;2:CD000967
   Google Scholar
• El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578
   PubMedGoogle Scholar
• Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;4:CD001945
   Google Scholar
• Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000059
   Google Scholar
• THieda P, Beard S, Richter A, et al. An economic review of compliance therapy with medication in the treatment of schizophrenia. Psych Serv 2003;54:508-16
   PubMed Web of Science ®Google Scholar
• Dolder C, Lacro J, Dunn L, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Schooler N, Rabinowitz J, Davidson M, et al. Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-53
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Oehl M, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64:S3-S9
   Google Scholar
• Remington G, Adams M. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40:S5-S11
   PubMed Web of Science ®Google Scholar
• Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995;9(Suppl 5):17-20
   PubMed Web of Science ®Google Scholar
• Vazquez-Polo FJ, Negrin M, Cabases JM, et al. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ 2005;8:153-65
   PubMed Web of Science ®Google Scholar
• Boletin Oficial de Murcia. 2009
   Google Scholar
• Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16
   PubMedGoogle Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-55
   PubMed Web of Science ®Google Scholar
• Janicak PG, Wu JH, Mao L. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Curr Med Res Opin 2008;24:1807-15
   PubMed Web of Science ®Google Scholar
• Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ 2002;324:250-2
   PubMed Web of Science ®Google Scholar
• Bobes J, Garcia-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-47
   PubMed Web of Science ®Google Scholar
• Ucok A, Incesu C, Aker T, et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 2007;22(5):328-33. Epub 2007 Mar 6
   PubMedGoogle Scholar
• Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Mason P, Harrison G, Glazebrook C, et al. The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISos) coordinated by the World Health Organisation. Br J Psychiatry 1996;169:580-6
   PubMed Web of Science ®Google Scholar